Search Results - "Mario Barugel"

A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer by Antelo, Marina, Balaguer, Francesc, Shia, Jinru, Shen, Yan, Hur, Keun, Moreira, Leticia, Cuatrecasas, Miriam, Bujanda, Luis, Giraldez, Maria Dolores, Takahashi, Masanobu, Cabanne, Ana, Barugel, Mario Edmundo, Arnold, Mildred, Roca, Enrique Luis, Andreu, Montserrat, Castellvi-Bel, Sergi, Llor, Xavier, Jover, Rodrigo, Castells, Antoni, Boland, C Richard, Goel, Ajay

“…Early-onset colorectal cancer (CRC) represents a clinically distinct form of CRC that is often associated with a poor prognosis. Methylation levels of genomic…”
Get full text

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study by DOUILLARD, Jean-Yves, SIENA, Salvatore, RIVERA, Fernando, KOCAKOVA, Ilona, RUFF, Paul, BLASINSKA-MORAWIEC, Maria, SMAKAL, Martin, CANON, Jean-Luc, ROTHER, Mark, OLINER, Kelly S, WOLF, Michael, GANSERT, Jennifer, CASSIDY, James, TABERNERO, Josep, BURKES, Ronald, BARUGEL, Mario, HUMBLET, Yves, BODOKY, György, CUNNINGHAM, David, JASSEM, Jacek

“…Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved as…”
Get full text

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer by Douillard, Jean-Yves, Oliner, Kelly S, Siena, Salvatore, Tabernero, Josep, Burkes, Ronald, Barugel, Mario, Humblet, Yves, Bodoky, Gyorgy, Cunningham, David, Jassem, Jacek, Rivera, Fernando, Kocákova, Ilona, Ruff, Paul, Błasińska-Morawiec, Maria, Šmakal, Martin, Canon, Jean Luc, Rother, Mark, Williams, Richard, Rong, Alan, Wiezorek, Jeffrey, Sidhu, Roger, Patterson, Scott D

“…Patients who have colorectal cancer with RAS mutations in exon 2 are unlikely to respond to EGFR blockers. A retrospective analysis of tumors containing other,…”
Get full text

Metastatic colorectal cancer: recent advances in its clinical management by Barugel, Mario E, Vargas, Carlos, Krygier Waltier, Gabriel

“…Colorectal cancer (CRC) is frequently complicated by metastatic disease, with the liver being the most common site of metastasis. Surgical resection is the…”
Get full text

Increased Line-1 Hypomethylation is a Unique Feature of Early-Onset Colorectal Cancer (CRC) by Balaguer, Francesc, Antelo, Marina, Shen, Yan, Hur, Keun, Giraldez, Maria Dolores, Bujanda, Luis, Takahashi, Masanobu, Cabanne, Ana M, Barugel, Mario E, Arnold, Millie A, Roca, Enrique L, Andreu, Montserrat, Llor, Xavier, Jover, Rodrigo, Castells, Antoni, Boland, C. Richard, Goel, Ajay

Get full text

Prognostic factors of long-term outcomes after primary chemo-radiotherapy in non-metastatic anal squamous cell carcinoma: An international bicentric cohort by Iseas, Soledad, Prost, Diego Martín, Bouchereau, Sarah, Golubicki, Mariano, Robbio, Juan, Oviedo, Ana, Coraglio, Mariana, Carballido, Marcela, Kujaruk, Mirta, Mendez, Guillermo, Barugel, Mario Edmundo, Roca, Enrique, Gros, Louis, de Parades, Vincent, Baba-Hamed, Nabil, Adam, Julien, Abba, Martin C, Raymond, Eric

“…e15501 Background: Anal squamous cell carcinoma (ASCC) is a rare malignancy with a rising incidence associated with Human papillomavirus (HPV) infection…”
Get full text

Prevalence of KRAS and NRAS mutations in patients with metastatic colorectal cancer in Argentina: A multicenter prospective observational study by Marechal, Gabriela, Casarini, Ignacio, Gabriel, Astegiano Mario Gabriel, Pini, Alejandra, Duarte, Oscar D., Flores, Andres Eduardo, Bashkansky, Diego, Cifuentes, Paul, Venkatasubramanian, Indira, Barugel, Mario Edmundo

“…Abstract only…”
Get full text

Impact of body mass index (BMI) in a breast cancer Argentinian population by Mizrahi, Marvin Albert, Bianconi, Maria Ines, Micone, Paula, Barugel, Mario Edmundo, Storino, Claudio, Jankilevich, Gustavo

“…Abstract only…”
Get full text

RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data by Kafatos, George, Niepel, Daniela, Lowe, Kimberley, Jenkins-Anderson, Sophie, Westhead, Hal, Garawin, Tamer, Traugottová, Zuzana, Bilalis, Antonios, Molnar, Edit, Timar, Jozsef, Toth, Erika, Gouvas, Nikolaos, Papaxoinis, George, Murray, Samuel, Mokhtar, Nadia, Vosmikova, Hana, Fabian, Pavel, Skalova, Alena, Wójcik, Piotr, Tysarowski, Andrzej, Barugel, Mario, van Krieken, J Han, Trojan, Jörg

“…A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional,…”
Get full text

Moving foward and beyond the standard through a non-operative management in rectal cancer? Our watch and wait approach experience in Co-Recto by Iseas, Ilma Soledad, Carballido, Marcela, Coraglio, Mariana, Leiro, Fabio, Dieguez, Adriana, Eleta, Martin, Bianchi, Romina, Bertoncini, Cintia, Mendez, Guillermo Ariel, Barugel, Mario Edmundo, Roca, Enrique Luis

“…Abstract only…”
Get full text

Still Awaiting That Waiting Be a Validated Affordable Option in Rectal Cancer? Our Watch and Wait Approach Experience in Co-Recto by Soledad, Iseas, Marcela, Carballido, Mariana, Coraglio, Fabio, Leiro, Adriana, Dieguez, Martin, Eleta, Guillermo, Mendez, Ariel, Aguilo, Mario, Barugel, Enrique, Roca

Get full text

Definitive Concurrent Chemoradiation for Patients with Esophageal Squamous Cell Carcinoma. Experience at a Public Hospital in Argentina by Penayo, Rosa, Gallardo, Maximiliano SOSA, Mendez, Guillermo, O'Connor, Juan, Vitcopp, Gerardo, Carballido, Marcela, Barugel, Mario, Aguilo, Ariel, Oillataguerre, Lorena, Lobbe, Velia, Sardi, Mabel, Pogany, Catalina, Roca, Enrique

Get full text

Prevención del cáncer colorrectal (CCR) by Ubaldo Alfredo Gualdrini, Alicia Sambuelli, Mario Barugel, Alejandro Gutiérrez, Karina Collia Ávila

“…El cáncer colorrectal (CCR) ocupa el segundo lugar en mortalidad por tumores malignos en Argentina. El riesgo de padecer un CCR a través de toda la vida es de…”
Get full text

Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC) by Douillard, Jean-Yves, Siena, Salvatore, Tabernero, Josep, Burkes, Ronald L., Barugel, Mario Edmundo, Humblet, Yves, Bodoky, Gyorgy, Cunningham, David, Jassem, Jacek, Rivera, Fernando, Kocáková, Ilona, Ruff, Paul, Smakal, Martin, Canon, Jean-Luc, Rother, Mark, Oliner, Kelly S., Tian, Ying, Sidhu, Roger

“…Abstract only 3620 Background: The primary and final analyses of PRIME demonstrated that pmab + FOLFOX4 significantly improved progression-free survival (PFS)…”
Get full text

P-0282 Facing Rectal Cancer Under the Age of 50: Analysis of 140 Patients Discussed in an Multidisciplinary Team (Co-Recto) in Argentina by Iseas, Soledad, Antelo, Marina, Barugel, Mario, Aguilo, Ariel, Carballido, Marcela, Mendez, Guillermo, Dieguez, Adriana, Leiro, Fabio, Eleta, Martin, Coraglio, Mariana, Virginillo, Juan, Mospane, Claudio, Roca, Enrique

Get full text

Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC) by Douillard, Jean Yves, Siena, Salvatore, Tabernero, Josep, Burkes, Ronald L., Barugel, Mario Edmundo, Humblet, Yves, Cunningham, David, Xu, Feng, Zhao, Zhongyun, Sidhu, Roger

“…Abstract only 531^ Background: Final PRIME results showed that pmab + CT significantly improved progression-free survival (PFS) and objective response rate vs…”
Get full text

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC) by Oliner, Kelly S., Douillard, Jean-Yves, Siena, Salvatore, Tabernero, Josep, Burkes, Ronald L., Barugel, Mario Edmundo, Humblet, Yves, Bodoky, Gyorgy, Cunningham, David, Jassem, Jacek, Rivera, Fernando, Kocáková, Ilona, Ruff, Paul, Blasinska-Morawiec, Maria, Smakal, Martin, Williams, Richard Thomas, Rong, Alan, Wiezorek, Jeffrey S., Sidhu, Roger, Patterson, Scott D.

“…Abstract only 3511 Background: Analysis of a phase III pmab monotherapy study indicated that KRAS and NRAS mutations beyond KRAS exon 2 may be predictive of…”
Get full text

Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCRC) by Oliner, Kelly, Douillard, Jean-Yves, Siena, Salvatore, Tabernero, Josep, Burkes, Ronald, Barugel, Mario, Humblet, Yves, Bodoky, György, Cunningham, David, Jassem, Jacek, Rivera, Fernando, kocakova, Ilona, Ruff, Paul, Morawiec, Maria Blasinska, Smakal, Martin, Williams, Richard, Rong, Alan, Wiezorek, Jeffrey, Sidhu, Roger, Patterson, Scott

Get full text

El tratamiento de los pacientes con carcinoma epidermoide del canal anal en los últimos 20 años en nuestro hospital by Hui Jer Hwang, Claudia Bestani, René Jiménez, Guillermo Masciángioli, Alejandro Gutiérrez, Cristina Cartelli, Luisa Rafailovici, Mario Barugel, Gabriela Rodríguez, Guillermo Méndez

“…El carcinoma epidermoide del canal anal (CCA) constituye el 1.5% de los cánceres del sistema digestivo. La mayoría de los pacientes puede acceder a la cura a…”
Get full text

Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study by Carraro, Silvia, Roca, Enrique L, Cartelli, Cristina, Rafailovici, Luisa, Castillo Odena, Socorro, Wasserman, Ernesto, Gualdrini, Ubaldo, Huertas, Eduardo, Barugel, Mario, Ballarino, Graciela, Rodriguez, María C, Masciangioli, Guillermo

“…Oxaliplatin (OXA)/5-fluorouracil (5-FU) have confirmed their preclinical synergy in advanced colorectal cancer patients. Chemoradiotherapy with 5-FU +…”
Get more information